Antihypertensive medications, bone mineral density, and fractures: A review of old cardiac drugs that provides new insights into osteoporosis

Endocrine

Volumn 46, Issue 3, 2014, Pages 397-405

  Ghosh, Mahua ^a   Majumdar, Sumit R ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b 5 134B Clinical Science Building   (Canada)

Author keywords

Bone health; Cardiovascular medications; Fractures; Hypertension; Osteoporosis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOTEROL; FOSINOPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN;

BONE DENSITY; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; DRUG MECHANISM; FRACTURE; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRESCRIPTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; COMPLICATION; DRUG EFFECTS; OSTEOPOROTIC FRACTURES;

ANTIHYPERTENSIVE AGENTS; BONE DENSITY; HUMANS; HYPERTENSION; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES;

EID: 84904548239     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0167-4     Document Type: Review

References (94)

1. A. Parthan, M. Kruse, N. Yurgin, J. Huang, H.N. Viswanathan, D. Taylor, Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl. Health Econ. Health Policy 5, 485-497 (2013)
2. S.H. Choi, J.H. An, S. Lim, B.K. Koo, S.E. Park, H.J. Chang, S.I. Choi, Y.J. Park, K.S. Park, H.C. Jang, C.S. Shin, Lower bone mineral density is associated with higher coronary calcification and coronary plaque burdens by multidetector row coronary computed tomography in pre- and postmenopausal women. Clin. Endocrinol. (Oxf). 5, 644-651 (2009)
3. K. Nishio, S. Mukae, S. Aoki, S. Itoh, N. Konno, K. Ozawa, R. Satoh, T. Katagiri, Congestive heart failure is associated with the rate of bone loss. J. Intern. Med. 253, 439-446 (2003)
4. P. von der Recke, M.A. Hansen, C. Hassager, The association between low bone mass at the menopause and cardiovascular mortality. Am. J. Med. 106, 273-278 (1999)
5. L.M. Banks, B. Lees, J.E. MacSweeney, J.C. Stevenson, Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease? Eur. J. Clin. Invest. 24, 813-817 (1994)
6. A. Aoki, M. Murata, T. Asano, A. Ikoma, M. Sasaki, T. Saito, T. Otani, S. Jinbo, N. Ikeda, M. Kawakami, S.E. Ishikawa, Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. Cardiovasc. Diabetol. 12, 11 (2013)
7. S. Yang, N.D. Nguyen, J.R. Center, J.A. Eisman, T.V. Nguyen. Association between hypertension and fragility fracture: a longitudinal study. Osteoporos Int. (2013). doi: 10.1007/s00198-013-2457-8
8. F.P. Cappuccio, E. Meilahn, J.M. Zmuda, J.A. Cauley, High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet 354, 971-975 (1999)
9. S.R. Majumdar, J.A. Ezekowitz, L.M. Lix, W.D. Leslie, Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures: population-based cohort study of 45,509 subjects. J. Clin. Endocrinol. Metab. 97, 1179-1186 (2012)
10. X. Girerd, O. Hanon, B. Pannier, B. Vaïsse, J.J. Mourad, Trends in the use of antihypertensive drugs in France from 2002 to 2012: FLAHS surveys. Ann. Cardiol. Angeiol. 2, 210-214 (2013)
11. Q. Gu, V.L. Burt, C.F. Dillon, S. Yoon, Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation 126, 2105-2114 (2012)
12. N. Sreedharan, P.G. Rao, N.R. Rau, P.R. Shankar, Antihypertensive prescribing preferences in three South Indian Hospitals: cost analysis, physicians perspectives and emerging trends. Int. J. Clin. Pharmacol. Ther. 49, 277-285 (2011)
13. S. Middler, C.Y. Pak, F. Murad, F.C. Bartter, Thiazide diuretics and calcium metabolism. Metabolism 22, 139-146 (1973)
14. C. Bazzini, V. Vezzoli, C. Sironi et al., Thiazide-sensitive NaCl-cotransporter in the intestine: possible role of hydrochlorothiazide in the intestinal Ca2+ uptake. J. Biol. Chem. 280, 19902-19910 (2005)
15. N. Obermüller, P. Bernstein, H. Velázquez, R. Reilly, D. Moser, D.H. Ellison, S. Bachmann, Expression of the thiazide-sensitive Na-Cl cotransporter in rat and human kidney. Am. J. Physiol. 269, 900-910 (1995)
16. X.Y. Wang, S. Masilamani, J. Nielsen, T.H. Kwon, H.L. Brooks, S. Nielsen, M.A. Kneppe, The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J. Clin. Invest. 108, 215-222 (2001)
17. M.M. Dvorak, C. De Joussineau, D.H. Carter, Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J. Am. Soc. Nephrol. 18, 2509-2516 (2007)
18. E.L. Barry, F.A. Gesek, M.R. Kaplan, S.C. Hebert, P.A. Friedman, Expression of the sodium-chloride cotransporter in osteoblast-like cells: effect of thiazide diuretics. Am. J. Physiol. 272, C109-C116 (1997)
19. R. Aubin, P. Menard, D. Lajeunesse, Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 50, 1476-1482 (1996)
20. L. Rejnmark, P. Vestergaard, A.R. Pedersen, L. Heickendorff, F. Andreasen, L. Mosekilde, Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, doubleblinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur. J. Clin. Invest. 33, 41-50 (2003)
21. L. Rejnmark, P. Vestergaard, L. Heickendorff, F. Andreasen, L. Mosekilde, Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J. Intern. Med. 250, 144-153 (2001)
22. R. Wasnich, J. Davis, P. Ross, J. Vogel, Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ 301, 1303-1305 (1990)
23. R.D. Wasnich, J.W. Davis, Y.F. He, H. Petrovich, P.D. Ross, A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women. Osteoporos. Int. 5, 247-251 (1995)
24. G. Sigurdsson, L. Franzson, Increased bone mineral density in a population-based group of 70-year-old women on thiazide diuretics, independent of parathyroid hormone levels. J. Intern. Med. 250, 51-56 (2001)
25. K. Aung, T. Htay, Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst. Rev. 10, CD005185 (2011)
26. C. Plata, P. Meade, N. Vazquez, S.C. Hebert, G. Gamba, Functional properties of the apical Na ?-K?-2Cl- cotransporter isoforms. J. Biol. Chem. 277, 11004-11012 (2002)
27. J.M. Chen, B.S. Heran, J.M. Wright, Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database Syst. Rev. 4, CD007187 (2009)
28. L. Rejnmark, P. Vestergaard, L. Heickendorff, F. Andreasen, L. Mosekilde, Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover. J. Intern. Med. 257, 176-184 (2005)
29. J. Elmgreen, L. Tougaard, A. Leth, M.S. Christensen, Elevated serum parathyroid hormone concentration during treatment with high ceiling diuretics. Eur. J. Clin. Pharmacol. 18, 363-364 (1980)
30. L.S. Lim, H.A. Fink, T. Blackwell, B.C. Taylor, K.E. Ensrud, Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women. J. Am. Geriatr. Soc. 57, 855-862 (2009)
31. L.S. Lim, H.A. Fink, M.A. Kuskowski, B.C. Taylor, J.T. Schousboe, K.E. Ensrud, Loop diuretic use and increased rates of hip bone loss in older men: the osteoporotic fractures in men study. Arch. Intern. Med. 168, 735-740 (2008)
32. L. Rejnmark, P. Vestergaard, L. Heickendorff, F. Andreasen, L. Mosekilde, Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J. Bone Miner. Res. 21, 163-170 (2006)
33. S. Arampatzis, L.M. Gaetcke, G.C. Funk, C. Schwarz, M. Mohaupt, H. Zimmermann, A.K. Exadaktylos, G. Lindner, Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department. Maturitas. 75, 81-86 (2013)
34. D.H. Solomon, H. Mogun, K. Garneau, M.A. Fischer, Risk of fractures in older adults using antihypertensive medications. J. Bone Miner. Res. 26, 1561-1567 (2011)
35. L.J. Min, M. Mogi, J.M. Li, J. Iwanami, M. Iwai, M. Horiuchi, Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 97, 434-442 (2005)
36. P.H. Law, Y. Sun, S.K. Bhattacharya, V.S. Chhokar, K.T. Weber, Diuretics and bone loss in rats with aldosteronism. J. Am. Coll. Cardiol. 46, 142-146 (2005)
37. A.L. Runyan, V.S. Chhokar, Y. Sun, S.K. Bhattacharya, J.W. Runyan, K.T. Weber, Bone loss in rats with aldosteronism. Am. J. Med. Sci. 330, 1-7 (2005)
38. A.S. Salcuni, S. Palmieri, V. Carnevale, V. Morelli, C. Battista, V. Guarnieri, G. Guglielmi, G. Desina, C. Eller-Vainicher, P. Beck-Peccoz, A. Scillitani, I. Chiodini, Bone involvement in aldosteronism. J. Bone Miner Res. 27, 2217-2222 (2012)
39. L. Ceccoli, V. Ronconi, L. Giovannini, M. Marcheggiani, F. Turchi, M. Boscaro, G. Giacchetti, Bone health and aldosterone excess. Osteoporos Int. 24(11), 2801-2807 (2013)
40. L.D. Carbone, J.D. Cross, S.H. Raza, A.J. Bush, R.J. Sepanski, S. Dhawan, B.Q. Khan, M. Gupta, K. Ahmad, R.N. Khouzam, D.A. Dishmon, J.P. Nesheiwat, M.A. Hajjar, W.A. Chishti, W. Nasser, M. Khan, C.R. Womack, T. Cho, A.R. Haskin, K.T. Weber, Fracture risk in men with congestive heart failure risk reduction with spironolactone. J. Am. Coll. Cardiol. 52, 135-138 (2008)
41. O.E. Brodde, M.C. Michel, X.L. Wang, H.R. Zerkowski, Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion. J. Hypertens. Suppl. 6, S497-S500 (1988)
42. G. Engel, Subclasses of beta-adrenoceptors-a quantitative estimation of beta 1- and beta 2- adrenoceptors in guinea pig and human lung. Postgrad. Med. J. 57, 77-83 (1981)
43. S. Krief, F. Lönnqvist, S. Raimbault, B. Baude, A. Van Spronsen, P. Arner, A.D. Strosberg, D. Ricquier, L.J. Emorine, Tissue distribution of beta 3-adrenergic receptor mRNA in man. J. Clin. Invest. 91, 344-349 (1993)
44. R.E. Moore, C.K. Smith II, C.S. Bailey, E.F. Voelkel, A.H. Tashjian Jr., Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. 23, 301-315 (1993)
45. F.J. Conway, J.D. Fitzgerald, J. McAinsh, D.J. Rowlands, W.T. Simpson, Human pharmacokinetic and pharmacodynamic studies on the atenolol (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Br. J. Clin. Pharmacol. 3, 267-272 (1976)
46. A. Togari, M. Arai, Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption. J. Pharmacol. Sci. 106, 542-546 (2008)
47. A. Togari, M. Arai, A. Kondo, The role of the sympathetic nervous system in controlling bone metabolism. Exp. Opin. Ther. Targets. 9, 931-940 (2005)
48. S.J. Aitken, E. Landao-Bassonga, S.H. Ralston, A.I. Idris, Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Arch. Biochem. Biophys. 482, 96-103 (2009)
49. A. Togari, Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc. Res. Tech. 58, 77-84 (2002)
50. E.L. Hill, R. Turner, R. Elde, Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience 44, 747-755 (1991)
51. H.S. Sandhu, A. Kwong-Hing, M.S. Herskovits, I.J. Singh, The early effects of surgical sympathectomy on bone resorption in the rat incisor socket. Arch. Oral Biol. 35, 1003-1007 (1990)
52. H.S. Sandhu, M.S. Herskovits, I.J. Singh, Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat. Rec. 219, 32-38 (1987)
53. H.H. Huang, T.C. Brennan, M.M. Muir, R.S. Mason, Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J. Cell. Physiol. 220, 267-275 (2009)
54. W.F. Rodrigues, M.F. Madeira, T.A. da Silva, J.T. Clemente-Napimoga, C.B. Miguel, V.J. Dias-da-Silva, O. Barbosa-Neto, A.H. Lopes, M.H. Napimoga, Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation. Br. J. Pharmacol. 165, 2140-2151 (2012)
55. S. Yang, N.D. Nguyen, J.R. Center, J.A. Eisman, T.V. Nguyen, Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 48, 451-455 (2011)
56. H.J. Song, J. Lee, Y.J. Kim, S.Y. Jung, H.J. Kim, N.K. Choi, B.J. Park, β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients. Bone 51, 1008-1015 (2012)
57. S. Yang, N.D. Nguyen, J.A. Eisman, T.V. Nguyen, Association between beta-blockers and fracture risk: a Bayesian meta-analysis. Bone 51, 969-974 (2012)
58. K.A. Toulis, K. Hemming, S. Stergianos, K. Nirantharakumar, J.P. Bilezikian, β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int. (2013). doi:10.1007/s00198-013-2498-z
59. R. Hatton, M. Stimpel, T.J. Chambers, Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J. Endocrinol. 152, 5-10 (1997)
60. H. Nakagami, M.K. Osako, R. Morishita, Potential effect of angiotensin II receptor blockade in adipose tissue and bone. Curr. Pharm. Des. 19, 3049-3053 (2013)
61. H. Shimizu, H. Nakagami, M.K. Osako, F. Nakagami, Y. Kunugiza, T. Tomita, H. Yoshikawa, H. Rakugi, T. Ogihara, R. Morishita, Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens. Res. 32, 786-790 (2009)
62. H. Shimizu, H. Nakagami, M.K. Osako, R. Hanayama, Y. Kunugiza, T. Kizawa, T. Tomita, H. Yoshikawa, T. Ogihara, R. Morishita, Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 22, 2465-2475 (2008)
63. H. Nakagami, R. Morishita, Hormones and osteoporosis update. Effect of angiotensin II on bone metabolism. Clin. Calcium. 19, 997-1002 (2009)
64. L. Ma, J.L. Ji, H. Ji, X. Yu, L.J. Ding, K. Liu, Y.Q. Li, Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. Bone 47, 5-11 (2010)
65. A. García-Testal, A. Monzó, G. Rabanaque, A. González, A. Romeu, Evolution of the bone mass of hypertense menopausal women in treatment with fosinopril. Med. Clin. (Barc). 127, 692-694 (2006)
66. H. Lynn, T. Kwok, S.Y. Wong, J. Woo, P.C. Leung, Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38, 584-588 (2006)
67. T. Kwok, J. Leung, Y.F. Zhang, D. Bauer, K.E. Ensrud, E. Barrett-Connor, P.C. Leung, Osteoporotic Fractures in Men (MrOS) Research Group. Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporos. Int. 23, 2159-2167 (2012)
68. L. Rejnmark, P. Vestergaard, L. Mosekilde, Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J. Hypertens. 24, 581-589 (2006)
69. M. Wiens, M. Etminan, S.S. Gill, B. Takkouche, Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J. Intern. Med. 260, 350-362 (2006)
70. N. Himori, N. Taira, Differential effects of the calcium-antagonistic vasodilators, nifedipine and verapamil, on the tracheal musculature and vasculature of the dog. Br. J. Pharmacol. 68, 595-597 (1980)
71. K.L. Schulte, E. Laber, W.A. Meyer-Sabellek, A. Distler, R. Gotzen, Specific alpha-adrenoceptor-mediated vasoconstriction in human veins and interaction with the calcium entry blockers nifedipine and diltiazem. J. Hypertens. Suppl. 3, S239-S241 (1985)
72. A.E. Minocherhomjee, B.D. Roufogalis, Antagonism of calmodulin and phosphodiesterase by nifedipine and related calcium entry blockers. Cell Calcium 5, 57-63 (1984)
73. H.J. Kramer, K. Glänzer, T. Freitag, J. Schönfeld, M. Sorger, H. Schlebusch, R. Düsing, F. Krück, Studies on the role of sodium-and potassium-activated adenosine triphosphatase inhibition in the pathogenesis of human hypertension. Changes in vascular and cardiac function following inhibition of the sodium pump in normotensive subjects and effects of calcium entry blockade. Klin Wochenschr. 63, 32-36 (1985)
74. D.C. Warltier, H.F. Hardman, H.L. Brooks, G.J. Gross, Transmural gradient of coronary blood flow following dihydropyridine calcium antagonists and other vasodilator drugs. Basic Res. Cardiol. 78, 644-653 (1983)
75. T. Hedner, Calcium channel blockers: spectrum of side effects and drug interactions. Acta Pharmacol. Toxicol. (Copenh). 58(Suppl 2), 119-130 (1986)
76. T. Kameda, H. Mano, Y. Yamada, H. Takai, N. Amizuka, M. Kobori, N. Izumi, H. Kawashima, H. Ozawa, K. Ikeda, A. Kameda, Y. Hakeda, M. Kumegawa, Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem. Biophys. Res. Commun. 245, 419-422 (1998)
77. N. Kosaka, M. Uchii, Effect of benidipine hydrochloride, a dihydropyridine-type calcium antagonist, on the function of mouse osteoblastic cells. Calcif. Tissue Int. 62, 554-556 (1998)
78. Z. Halici, B. Borekci, Y. Ozdemir, E. Cadirci, H. Suleyman, Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats. Eur. J. Pharmacol. 579, 241-245 (2008)
79. I. Gradosova, H. Zivna, V. Palicka, S. Hubena, K. Svejkovska, P. Zivny, Protective effect of amlodipine on rat bone tissue after orchidectomy. Pharmacology 89, 37-43 (2012)
80. K. Ushijima, Y. Liu, T. Maekawa, E. Ishikawa, Y. Motosugi, H. Ando, S. Tsuruoka, A. Fujimura, Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats. Eur. J. Pharmacol. 635, 227-230 (2010)
81. S.A. Ay, M. Karaman, M. Cakar, S. Balta, E. Arslan, F. Bulucu, S. Demirbas, T. Celik, M.I. Naharci, S. Demirkol, O. Kurt, E. Bozoglu, Amlodipine increases vitamin D levels more than valsartan in newly diagnosed hypertensive patients: pointing to an additional effect on bone metabolism or a novel marker of inflammation? Ren. Fail. 35, 691-696 (2013)
82. S. Zacharieva, R. Shigarminova, E. Nachev, Z. Kamenov, I. Atanassova, M. Orbetzova, A. Stoynev, N. Doncheva, A.M. Borissova, Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause. Methods Find. Exp. Clin. Pharmacol. 25, 209-213 (2003)
83. I. Zofková, R.L. Kancheva, The effect of nifedipine on serum parathyroid hormone and calcitonin in postmenopausal women. Life Sci. 57, 1087-1096 (1995)
84. M.M. Albers, W. Johnson, V. Vivian, R.D. Jackson, Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. Bone 12, 39-42 (1991)
85. K.A. Hanafy, J.S. Krumenacker, F. Murad, NO, nitrotyrosine, and cyclic GMP in signal transduction. Med. Sci. Monit. 7, 801-819 (2001)
86. J. Abrams, Nitroglycerin and long-acting nitrates in clinical practice. Am. J. Med. 74, 85-94 (1983)
87. S.H. Ralston, D. Todd, M. Helfrich, N. Benjamin, P.S. Grabowski, Human osteoblast-like cells produce nitric oxide and express inducible nitric oxide synthase. Endocrinology 135, 330-336 (1994)
88. C.W. Löwik, P.H. Nibbering, M. van de Ruit, S.E. Papapoulos, Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J. Clin. Invest. 93, 1465-1472 (1994)
89. S.J. Wimalawansa, G. De Marco, P. Gangula, C. Yallampalli, Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 18, 301-304 (1996)
90. M. Hukkanen, L.A. Platts, T. Lawes, S.I. Girgis, Y.T. Konttinen, A.E. Goodship, I. MacIntyre, J.M. Polak, Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Bone 32, 142-149 (2003)
91. S.A. Jamal, W.S. Browner, D.C. Bauer, S.R. Cummings, Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J. Bone Miner. Res. 13, 1755-1759 (1998)
92. L. Rejnmark, P. Vestergaard, L. Mosekilde, Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J. Bone Miner. Res. 21, 1811-1817 (2006)
93. S.A. Jamal, S.R. Cummings, G.A. Hawker, Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J. Bone Miner. Res. 19, 1512-1517 (2004)
94. S. Pouwels, A. Lalmohamed, T. van Staa, C. Cooper, P. Souverein, H.G. Leufkens, L. Rejnmark, A. de Boer, P. Vestergaard, F. de Vries, Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J. Clin. Endocrinol. Metab. 95, 1924-1931 (2010)